Foundayo and Zepbound now covered for millions of Americans
About Foundayo™ (orforglipron)3 Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have…
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
“This expansion reflects the strength of a long-standing partnership between Lilly and the state of Indiana – one…
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access
New, lower list price of $675 per month across Wegovy®, Ozempic®, and Rybelsus®, effective January 1, 2027, addresses…